Methods and systems for classification and treatment of small cell lung cancer

JP2023548590A5Inactive Publication Date: 2024-11-12BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527276
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

Aspects of the present disclosure are directed to methods for classifying and treating small cell lung cancer (SCLC). Particular aspects relate to treating subjects with SCLC using targeting agents against cell surface proteins, where the targeting agents are selected based on SCLC subtype classification. Methods are disclosed for identifying subjects as having SCLC subtypes (e.g., SCLC-A, SCLC-N, SCLC-P, SCLC-I) and administering targeting agents configured to target cell surface proteins associated with the identified SCLC subtype. Also disclosed are compositions comprising targeting agents for treating SCLC. TIFF2023548590000114.tif60170
Need to check novelty before this filing date? Find Prior Art

Claims

1. A composition for treating a subject for small cell lung cancer (SCLC), comprising a targeting agent capable of specifically binding to DLL3, CEACAM5, or SCNN1A, or a targeting agent capable of specifically binding to one or more of the proteins in Table 1, Table 2, or Table 3, wherein the subject is determined to have SCLC-A.

2. The composition of claim 1, wherein the targeting agent is capable of specifically binding to DLL3, CEACAM5, or SCNN1A.

3. The composition of any one of claims 1 to 2, wherein the subject is determined to have SCLC-A by detecting expression of ASCL1 from cancer cells derived from the subject.

4. A composition for treating a subject for SCLC, the composition comprising a targeting agent capable of specifically binding to CD276 or a targeting agent capable of specifically binding to one or more of the proteins in Table 10, Table 11, or Table 12, wherein the subject has been determined to have SCLC-I.

5. The composition of claim 4, wherein the targeting agent is capable of specifically binding to SLAMF8, MRC2, or PIEZO1.

6. The composition of any one of claims 4 to 5, wherein the subject has been determined to have SCLC-I by confirming that cancer cells derived from the subject do not express any of POU2F3, NEUROD1, or ASCL1.

7. A composition for treating a subject for SCLC, the composition comprising a targeting agent capable of specifically binding to SEZ6 or a targeting agent capable of specifically binding to one or more of the proteins of Table 4, Table 5, or Table 6, wherein the subject has been determined to have SCLC-N.

8. The composition of claim 7, wherein the targeting agent is capable of specifically binding to SSTR2, SEMA6D, or SGCD.

9. The composition according to any one of claims 7 to 8, wherein the subject is determined to have SCLC-N by detecting expression of NEUROD1 from cancer cells derived from the subject.

10. A composition for treating a subject for SCLC, the composition comprising a targeting agent capable of specifically binding to TACSTD2 or a targeting agent capable of specifically binding to one or more of the proteins in Table 7, Table 8, or Table 9, wherein the subject has been determined to have SCLC-P.

11. The composition of claim 10, wherein the targeting agent is capable of specifically binding to MICA, TMEM87A, or ART3.

12. The composition of any one of claims 10 to 11, wherein the subject is determined to have SCLC-P by detecting expression of POU2F3 from cancer cells derived from the subject.

13. The composition of any one of claims 1 to 12, wherein the targeting agent comprises an antibody or a fragment thereof.

14. The composition of any one of claims 1 to 12, wherein the targeting agent is a bispecific T cell engager.

15. The composition of any one of claims 1 to 14, wherein the composition comprises cells containing a targeting agent.

16. The composition of claim 15, wherein the cell is an immune cell.

17. The composition of claim 16, wherein the immune cell is a T cell or a NK cell.

18. The composition of any one of claims 15 to 17, wherein the targeting agent is a chimeric antigen receptor or a T cell receptor.

19. The composition of any one of claims 1 to 18, wherein the targeting agent is operably linked to a therapeutic agent.

20. 20. The composition of claim 19, wherein the therapeutic agent is a chemotherapeutic agent, a toxin, or a therapeutic nucleic acid.

21. The composition of any one of claims 1 to 20, wherein the targeting agent is an antibody-drug conjugate or an antibody-oligonucleotide conjugate.